Driehaus Capital Management LLC Aerovate Therapeutics, Inc. Transaction History

Driehaus Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.68 - $29.57 $4.65 Million - $7.78 Million	-263,217 Reduced 24.87%	794,992 $23.5 Million
Q4 2023 Feb 14, 2024	SELL	$9.58 - $24.25 $1.24 Million - $3.14 Million	-129,409 Reduced 10.9%	1,058,209 $23.9 Million
Q3 2023 Nov 14, 2023	SELL	$12.9 - $18.88 $83,501 - $122,210	-6,473 Reduced 0.54%	1,187,618 $16.1 Million
Q2 2023 Aug 14, 2023	BUY	$15.63 - $22.01 $18.7 Million - $26.3 Million	1,194,091 New	1,194,091 $20.5 Million
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $692,181 - $1.21 Million	46,864 New	46,864 $777,000

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $63.6M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.